Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 10/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | CKS1B | P61024 | 1/20 | 0.50 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 3/20 | 0.48 |
| ▸ | CA2 | P00918 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2990491 | 0.99 | MPO (0.64) | MPOHPGDALDH1A1TP53CYP1A2 | |
| SCHEMBL28857917 | 0.91 | MPO (0.66) | MPOHPGDALDH1A1TP53CYP1A2 | |
| SCHEMBL2290857 | 0.84 | BCHE (0.60) | MPOHPGDALDH1A1LMNAKMT2A | |
| SCHEMBL8324095 | 0.83 | ALDH1A1 (0.69) | HPGDALDH1A1TP53CYP1A2CYP3A4 | |
| SCHEMBL4933368 | 0.82 | MEN1 (0.68) | HPGDALDH1A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL8319293 | 0.81 | CYP4A11 (0.60) | HPGDALDH1A1TP53CYP1A2CYP3A4 | |
| SCHEMBL3310683 | 0.80 | LMNA (0.64) | HPGDALDH1A1LMNACA1CA2 | |
| SCHEMBL4932422 | 0.79 | KMT2A (0.73) | CYP1A2CYP2C19LMNAKMT2AMEN1 | |
| SCHEMBL15270421 | 0.79 | CA1 (0.64) | HPGDALDH1A1TP53CYP1A2CYP3A4 | |
| SCHEMBL2579068 | 0.79 | KEAP1 (0.56) | HPGDALDH1A1TP53CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7998988-B2 | Biphenyl compounds useful in the treatment or prevention of cardiovascular disorders | BAYER SCHERING PHARMA AKTIENGELLSCHAFT (DE) | 2011-08-16 | — | — | US | disclosed |
| US-20090227640-A1 | Heterocyclic compounds with carboxyl isostere groups and their use for the treatment of cardiovascular diseases | BAYER HEALTHCARE AG (DE) | 2009-09-10 | — | — | US | disclosed |
| US-7329777-B2 | Methods for treating heart failure, thromboembolic disorders, and pulmonary fibrosis | BAYER AKTIENGESELLSCHAFT (DE) | 2008-02-12 | — | — | US | disclosed |
| US-20050288366-A1 | Novel aminodicarboxylic acid derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2005-12-29 | — | — | US | disclosed |
| US-6939989-B2 | Side-chain halogenated amino dicarboxylic acid derivatives as medicaments for treating cardiovascular diseases | BAYER AKTIENGESELLSCHAFT (DE) | 2005-09-06 | — | — | US | disclosed |
| US-6939990-B2 | Derivatives of dicarboxylic acid having pharmaceutical properties | BAYER AKTIENGESELLSCHAFT (DE) | 2005-09-06 | — | — | US | disclosed |
| US-20040110840-A1 | Novel derivatives of dicarboxylic acid having pharmaceutical properties | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-06-10 | — | — | US | disclosed |
| US-20040082658-A1 | Side-chain halogenated amino dicarboxylic acid derivatives as medicaments for treating cardiovascular diseases | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227640-A1 | Heterocyclic compounds with carboxyl isostere groups and their use for the treatment of cardiovascular diseases | TNNI3, PC, TNNT2 | MPO 735/4885HPGD 30/4885ALDH1A1 708/4885 |
| US-20040082658-A1 | Side-chain halogenated amino dicarboxylic acid derivatives as medicaments for treating cardiovascular diseases | BCAT2, BCAT1, AADAT | MPO 2460/4885HPGD 1988/4885ALDH1A1 322/4885 |
| US-20040110840-A1 | Novel derivatives of dicarboxylic acid having pharmaceutical properties | SDHA, GOT2, MDH2 | MPO 3831/4885HPGD 269/4885ALDH1A1 349/4885 |
| US-20050288366-A1 | Novel aminodicarboxylic acid derivatives | DDC, DAO, AADAT | MPO 2165/4885HPGD 310/4885ALDH1A1 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.